VASCULAR ANGIOTENSIN AT2RECEPTORS IN HYPERTENSION AND AGEING

Clinical and Experimental Pharmacology and Physiology - Tập 35 Số 4 - Trang 386-390 - 2008
Robert E. Widdop1, Antony Vinh1, Daniel Henrion2, Emma S. Jones1
1Department of Pharmacology, Monash University, Victoria, Australia and
2Department of Neurovascular Integrated Biology, Faculty of Medicine, University of Angers, France

Tóm tắt

SUMMARYAngiotensin II (Ang II) acts on both subtype 1 receptors (AT1R) and subtype 2 receptors (AT2R). AT1R stimulation mediates all of the classical actions of Ang II including vasoconstriction and cardiovascular hypertrophy. By contrast, AT2R stimulation is thought to exert a counter‐regulatory effect on AT1R and exert direct vasodilatation and antigrowth effects.In this brief review, the vascular effects of AT2R are reviewed in the context of recent data relating to hypertension and ageing.In particular the vascular AT2R phenotype in isolated mesenteric arteries may switch from that of relaxation to contraction in hypertension or ageing and this AT2R contractile phenotype can be converted to relaxation, at least with chronic antihypertensive treatment in spontaneously hypertensive rats.In vivodata pertaining to hypertension and ageing are consistent with vasodilator and antiremodelling effects of AT2R.

Từ khóa


Tài liệu tham khảo

De Gasparo M, 2000, International union of pharmacology. XXIII. The angiotensin II receptors, Pharmacol. Rev, 52, 415, 10.1016/S0031-6997(24)01458-3

10.1146/annurev.pa.36.040196.001433

Timmermans PB, 1991, Angiotensin II receptor antagonists. From discovery to antihypertensive drugs, Hypertension, 18, III136

Shibouta Y, 1993, Pharmacological profile of a highly potent and long‐acting angiotensin II receptor antagonist, 2‐ethoxy‐1‐[[2′‐(1H‐tetrazol‐5‐yl) biphenyl‐4‐yl]methyl]‐1H‐benzimidazole‐7‐carboxylic acid (CV‐11974), and its prodrug, (+/–)‐1‐(cyclohexyloxycarbonyloxy)‐ethyl 2‐ethoxy‐1‐[[2′‐(1H‐tetrazol‐5‐yl) biphenyl‐4‐yl]methyl]‐1H‐benzimidazole‐7‐carboxylate (TCV‐116), J. Pharmacol. Exp. Ther, 266, 114

Morsing P., 1999, Candesartan: A new‐generation angiotensin II AT1 receptor blocker: Pharmacology, antihypertensive efficacy, renal function, and renoprotection, J. Am. Soc. Nephrol, 10, S248

10.1016/0006-291X(89)92133-5

10.1016/j.peptides.2005.03.010

10.1161/01.HYP.0000159192.93968.8f

10.1038/sj.bjp.0705448

10.1161/01.HYP.0000033224.99806.8A

10.1097/01.hjh.0000251902.85675.7e

10.1161/hy1101.096109

10.1007/s11906-004-0086-5

10.1038/sj.bjp.0703371

10.1161/01.HYP.34.4.659

10.1161/01.HYP.33.1.366

10.1161/01.CIR.0000156503.62815.48

10.1161/01.HYP.31.1.349

10.1161/01.HYP.32.3.467

10.1161/01.HYP.34.5.1112

10.1161/hy1201.096576

10.1038/sj.bjp.0705838

10.1038/377744a0

10.1038/377748a0

10.1172/JCI7886

10.1016/j.yjmcc.2004.08.004

SavoiaC TouyzRM VolpeM SchiffrinEL.Angiotensin type 2 receptor in resistance arteries of type 2 diabetic Hypertensive Patients.Hypertension2006.

10.1161/01.CIR.0000128696.12245.57

10.1161/01.HYP.35.5.1069

10.1161/01.CIR.0000048893.62841.F7

10.1161/01.HYP.0000073843.56046.45

10.1210/en.139.5.2579

10.2165/00002512-199710060-00003

10.1016/j.regpep.2004.12.027

10.1161/01.HYP.0000128531.39964.c0

10.1038/sj.bjp.0702210

10.1038/sj.bjp.0705484

10.3317/jraas.2002.006

10.1161/HYPERTENSIONAHA.106.085035

Thông tin
Thông tin xuất bản

Clinical and Experimental Pharmacology and Physiology

Tập 35 Số 4

386-390

Thông tin tác giả